Shanghai Junshi Biosciences Stock Price To Sales
| 688180 Stock | 29.97 0.13 0.43% |
Shanghai Junshi Biosciences fundamentals help investors to digest information that contributes to Shanghai Junshi's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Junshi's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Junshi stock.
Shanghai | Price To Sales |
Shanghai Junshi Biosciences Company Price To Sales Analysis
Shanghai Junshi's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Shanghai Junshi Price To Sales | 14.29 X |
Most of Shanghai Junshi's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Junshi Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Shanghai Junshi Biosciences has a Price To Sales of 14.2866 times. This is 33.24% lower than that of the Biotechnology sector and 85.48% lower than that of the Health Care industry. The price to sales for all China stocks is 25.1% lower than that of the firm.
Shanghai Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Junshi's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Junshi could also be used in its relative valuation, which is a method of valuing Shanghai Junshi by comparing valuation metrics of similar companies.Shanghai Junshi is currently under evaluation in price to sales category among its peers.
Shanghai Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 24.9 B | ||||
| Shares Outstanding | 765.58 M | ||||
| Shares Owned By Insiders | 29.59 % | ||||
| Shares Owned By Institutions | 25.12 % | ||||
| Price To Book | 4.56 X | ||||
| Price To Sales | 14.29 X | ||||
| Revenue | 1.5 B | ||||
| Gross Profit | 1.45 B | ||||
| EBITDA | (1.61 B) | ||||
| Net Income | (2.25 B) | ||||
| Total Debt | 539.39 M | ||||
| Book Value Per Share | 28.15 X | ||||
| Cash Flow From Operations | (2.01 B) | ||||
| Earnings Per Share | (1.97) X | ||||
| Target Price | 39.0 | ||||
| Number Of Employees | 2.57 K | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 25.53 B | ||||
| Total Asset | 11.36 B | ||||
| Retained Earnings | (9.04 B) | ||||
| Working Capital | 3.07 B | ||||
| Net Asset | 11.36 B |
About Shanghai Junshi Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Junshi Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Junshi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Junshi Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Junshi financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Junshi security.